143 related articles for article (PubMed ID: 3815420)
1. Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide.
Berry J; Green BJ; Matheson DS
Cancer Immunol Immunother; 1987; 24(1):72-5. PubMed ID: 3815420
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
[TBL] [Abstract][Full Text] [Related]
3. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate SL
Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
[TBL] [Abstract][Full Text] [Related]
4. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma.
Santen RJ; Santner S; Davis B; Veldhuis J; Samojlik E; Ruby E
J Clin Endocrinol Metab; 1978 Dec; 47(6):1257-65. PubMed ID: 263348
[No Abstract] [Full Text] [Related]
5. Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer.
Berry J; Green BJ; Matheson DS
Eur J Cancer Clin Oncol; 1987 May; 23(5):517-20. PubMed ID: 3653175
[TBL] [Abstract][Full Text] [Related]
6. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate S
Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
[TBL] [Abstract][Full Text] [Related]
7. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
8. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
Dowsett M; Santner SJ; Santen RJ; Jeffcoate SL; Smith IE
Br J Cancer; 1985 Jul; 52(1):31-5. PubMed ID: 4015950
[TBL] [Abstract][Full Text] [Related]
9. Natural killer (NK) activity in peripheral blood lymphocytes of patients with benign and malignant breast disease.
White D; Jones DB; Cooke T; Kirkham N
Br J Cancer; 1982 Oct; 46(4):611-6. PubMed ID: 7138766
[TBL] [Abstract][Full Text] [Related]
10. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
Bruning PF; Bonfrer JM; De Jong-Bakker M; Nooyen W
J Steroid Biochem; 1984 Sep; 21(3):293-8. PubMed ID: 6092781
[TBL] [Abstract][Full Text] [Related]
11. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
12. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; Smith IE
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines.
Alvarado CS; Findley HW; Chan WC; Hnath RS; Abdel-Mageed A; Pais RC; Kutner MH; Ragab AH
Cancer; 1989 Jan; 63(1):83-9. PubMed ID: 2783377
[TBL] [Abstract][Full Text] [Related]
14. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Samojlik E; Santen RJ; Kirschner MA; Ertel NH
Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
Mani A; Roda J; Young D; Caligiuri MA; Fleming GF; Kaufman P; Brufsky A; Ottman S; Carson WE; Shapiro CL
Breast Cancer Res Treat; 2009 Sep; 117(1):83-9. PubMed ID: 19051009
[TBL] [Abstract][Full Text] [Related]
16. Thymostimulin increases natural cytotoxic activity in patients with breast cancer.
Meneses G; Delgado MA; Perez-Machado MA; Prieto A; Alonso R; Carrion F; Lanzos E; Alvarez-Mon M
Int J Immunopharmacol; 1997 Apr; 19(4):187-93. PubMed ID: 9373769
[TBL] [Abstract][Full Text] [Related]
17. [The use of aminoglutethimide in the treatment of metastatic breast cancer].
Bellora MG; Ciancio A; Ferrero A; Bergamino T; Zola P; Sismondi P
Minerva Ginecol; 1991 Dec; 43(12):589-93. PubMed ID: 1819778
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
19. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
20. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
Samojlik E; Santen RJ; Wells SA
J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
